Limited in Biological Technology

NeurogesX Reports Second Quarter 2009 Results

... Examples of such statements include, but are not limited to the timing and outcome of regulatory decisions ... risks and uncertainties, including, but not limited to; positive results in clinical trials may not ... regulatory approvals which are received may be limited to certain indications; NeurogesX' product ...

NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application

... Examples of such statements include, but are not limited to the timing and outcome of regulatory decisions ... risks and uncertainties, including, but not limited to; positive results in clinical trials may not ... regulatory approvals which are received may be limited to certain indications; NeurogesX' product ...

NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results

... Examples of such statements include, but are not limited to the timing and outcome of regulatory decisions ... risks and uncertainties, including, but not limited to the FDA may request additional clinical trials ... regulatory approvals which are received may be limited to certain indications; NeurogesX' product ...

Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors

... of formulations which would include, but not be limited to, collagen, demineralized bone matrices, ... or synthetic, which would include, but not be limited to, collagen, demineralized bone, allograft and ... with current protein therapy, which may be limited due to the inherent short half-life of a protein ...

Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009

... joint ventures with Aspen Pharmacare Holdings limited of South Africa. Total revenues for the ... if the disclosure of its financial results were limited to financial measures prepared only in accordance ... ventures with Aspen Pharmacare Holdings limited of South Africa. The remainder in each ...

BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol

... risk and uncertainty. These include, but are not limited to, statements related to the Company's ... to the differences include, but are not limited to, risks associated with Verenium's ... and Exchange Commission, including, but not limited to, the Company's quarterly report on Form 10-Q ...

Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech

... risks and uncertainties including, but not limited to, the risk that the company will not receive ... to differ materially include, but are not limited to, uncertainties associated with completing ... in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ...

Verenium Completes Amendment to 8% Senior Convertible Notes

... removing or modifying several restrictions that limited the Company's financial and operational ... risk and uncertainty. These include, but are not limited to, statements related to the Company's ... to the differences include, but are not limited to, risks associated with Verenium's ...

NeurogesX Added to Russell 3000 Index

... Examples of such statements include, but are not limited to the timing and outcome of regulatory decisions ... risks and uncertainties, including, but not limited to; positive results in clinical trials may not ... regulatory approvals which are received may be limited to certain indications; NeurogesX' product ...

Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer

... risks and uncertainties including, but not limited to, the risk that dose-limiting toxicities may be ... results to differ materially include, but are not limited to, uncertainties associated with completing ... in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ...

NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)

... Examples of such statements include, but are not limited to the timing and outcome of regulatory decisions ... risks and uncertainties, including, but not limited to; positive results in clinical trials may not ... regulatory approvals which are received may be limited to certain indications; NeurogesX' product ...

NeurogesX to Present at Needham Life Sciences Conference

... Examples of such statements include, but are not limited to, the expected timing and outcome of regulatory ... risks and uncertainties, including, but not limited to; positive results in clinical trials may not ... regulatory approvals which are received may be limited to certain indications; NeurogesX' product ...

Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting

... risks and uncertainties including, but not limited to, the risk that the rate of objective tumor ... for its product candidates include, but are not limited to, uncertainties associated with completing ... in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ...

NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS

... India and Western countries. Notwithstanding the limited size of the study the survival rate at 30 months ... statements. Such factors include, but are not limited to, changing market conditions, the successful ... forward-looking statements include but are not limited to the following: that nimotuzumab will continue ...

Phosphagenics Announces Completion of Transdermal Patch Prototypes

... May 29 /PRNewswire-FirstCall/ -- Phosphagenics limited ("Phosphagenics") (ASX: POH; OTCQX: PPGNY) today ... AND NOTES TO EDITORS About Phosphagenics limited Phosphagenics is a Melbourne-based, globally ... Brian Ritchie Phosphagenics limited FD Chief Operating Officer ...

YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING

... with head and neck cancer conducted by Biocon limited (Bangalore, India), a licensee of CIMAB SA, YM's ... statements. Such factors include, but are not limited to, changing market conditions, the successful ... forward-looking statements include but are not limited to the following: that nimotuzumab will continue ...

NeurogesX Receives European Commission Approval for Qutenza(TM)

... for adults who have diabetes as there is only limited experience with Qutenza in patients with Painful ... to treat and current treatment options may be limited by the need for frequent dosing and undesirable ... Examples of such statements include, but are not limited to, NeurogesX' plans to seek and timing to obtain ...

ROCK STARS OF SCIENCE: Prana's Co-Founding Scientist, Rudy Tanzi Teams up with Star-Powered Cast in GQ Photoshoot

... disease." About Prana Biotechnology limited Prana Biotechnology was established to ... statements. Such statements include, but are not limited to any statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of ...

The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders

... New Strategic Focus" and "they appear to have limited business experience in the United States." One ... as Biovail would lead shareholders to believe, as limited business experience in the United States. With ... materialize. Such factors include, but are not limited to, economic, business, technological, ...

Kibow Biotech, Inc. to Present at BIO 2009 International Convention: Innovations to Heal, Fuel, and Feed the World

... due to a number of factors including but not limited to the possibility that Kibow Biotics may not ... show evidence of clinical activity in the current limited human trials or that data from patients enrolled ... in actual results include, but are not limited to, whether or not the Company or any of its ...

YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS

... also began receiving royalty payments from a limited sales program in Europe initiated in the fourth ... statements. Such factors include, but are not limited to, changing market conditions, the successful ... forward-looking statements include but are not limited to the following: that nimotuzumab will continue ...

Avian Adenovirus Genotyping Diagnostic Service

... x-OvO limited has developed a centralised genotyping diagnostic ... (PRWEB) May 8, 2009 -- x-OvO limited is pleased to announce the launch of a novel ... of these possible relationships, x-OvO limited has developed a centralised diagnostic service ...

NeurogesX Reports First Quarter 2009 Results

... Examples of such statements include, but are not limited to, the expected timing and outcome of regulatory ... risks and uncertainties, including, but not limited to, positive results in clinical trials, or the ... approvals which are received may offer more limited indications than anticipated; unexpected ...

NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results

... Examples of such statements include, but are not limited to, the expected benefits of NeurogesX' product ... risks and uncertainties, including, but not limited to; positive results in clinical trials may not ... regulatory approvals which are received may be limited to certain indications; NeurogesX' product ...

Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009

... large customers may face, as well as to a more limited extent by economic and credit market conditions. ... to one of our largest customers, and to a more limited extent due to negative currency impact relating ... and capital structure, including, but not limited to, securing interim senior secured financing for ...

NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting

... to treat and current treatment options are often limited by poor tolerability, the need for titration, and ... Examples of such statements include, but are not limited to, the size, scope and growth of potential ... risks and uncertainties, including, but not limited to; positive results in clinical trials may not ...

Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial

... risks and uncertainties including, but not limited to, the risk that the rate of objective tumor ... results to differ materially include, but are not limited to, uncertainties associated with completing ... in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ...

STAAR Surgical Releases Afinity(TM) Collamer(R) Aspheric Single Piece NTIOL

... Other risks and uncertainties include our limited cash resources, the effect on our liquidity of ... reduce demand for all refractive procedures, our limited capital resources and limited access to financing, negative publicity resulting ...

Kibow Biotech, Inc. Launches Breakthrough Probiotic Dietary Supplement for Kidney Health in USA and Canada

... due to a number of factors including but not limited to the possibility that Kibow Biotics may not ... show evidence of clinical activity in the current limited human trials or that data from patients enrolled ... in actual results include, but are not limited to, whether or not the Company or any of its ...

Independent Study Corroborates Prana's Strategy to Treat Alzheimer's Disease Patients.

... 2009; 29 (13) About Prana Biotechnology limited Prana Biotechnology was established to ... statements. Such statements include, but are not limited to any statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of ...

WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results

... from what we currently anticipate include our limited operating history; failure to generate sufficient ... and services from AppTec; our reliance on a limited number of customers to continue to account for a ... projections in this release are based on limited information currently available to us, which is ...

Publication of Shire plc's Annual Report 2008

... The risks and uncertainties include, but are not limited to, risks associated with: the inherent ... of VYVANSE or ADDERALL XR include, but are not limited to: - faster than anticipated erosion of ... of amphetamine salts including but not limited to the ability to get sufficient quota from ...

Masimo Initiates Full Market Release of First-Ever Noninvasive Continuous Hemoglobin Monitor

... Success in limited Market Release Hospitals Highlights Early ... that have participated in the technology's limited market release initiated in September of 2008. ... around the world who participated in the limited market release. Ronald Miller, MD, Chief ...

NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update

... Examples of such statements include, but are not limited to, the expected timing of the European ... risks and uncertainties, including, but not limited to; positive results in clinical trials may not ... regulatory approvals which are received may be limited to certain indications; NeurogesX' product ...

NeurogesX' Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union

... neuropathic pain, current treatment options are limited by the need for frequent dosing, undesirable ... Examples of such statements include, but are not limited to, the expected timing of the European ... risks and uncertainties, including, but not limited to; positive results in clinical trials may not ...

BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results

... statements of historical facts, including but not limited to statements regarding the Company's competitive ... to uncertainties and risks including, but not limited to, operating performance, general financial, ... 745 Investment in Sunstone China limited -- 33,126 ...

PharmaNet Development Group Gives Notice of Anticipated Fundamental Change and Merger to Holders of Its Convertible Notes

... 12, 2009, JLL PharmaNet Holdings, LLC, a Delaware limited liability company ("Parent"), through PDGI ... to such differences include, but are not limited to, the expected timetable for completing the ... by the Securities and Exchange Commission, its limited insurance coverage in connection with the settled ...

Kibow Biotech Strongly Supports World Kidney Day for Maintenance of Healthy Kidney Function

... due to a number of factors including but not limited to the possibility that Kibow Biotics may not ... show evidence of clinical activity in the current limited human trials or that data from patients enrolled ... in actual results include, but are not limited to, whether or not the Company or any of its ...

Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008

... and capital structure, including, but not limited to, the secured senior secured financing ... to numerous uncertainties, including but not limited to: changes in drug-eluting coronary stent ... statements may involve, but are not limited to, comments with respect to our objectives and ...

Mindray Announces 2008 Fourth Quarter and Full Year Results

... -- Mindray Medical International limited (NYSE: MR ), a leading developer, manufacturer ... intangible assets including, but not limited to, in-progress research and development ... acquired intangible assets including, but not limited to, IPR&D, and restructuring charges, ...